Molecular Therapy of Virus-Associated Cancers, German Cancer Research Center (DKFZ), Heidelberg, Germany.
Faculty of Biosciences, Heidelberg University, Heidelberg, Germany.
mBio. 2019 Feb 12;10(1):e02323-18. doi: 10.1128/mBio.02323-18.
Hypoxia is linked to therapeutic resistance and poor clinical prognosis for many tumor entities, including human papillomavirus (HPV)-positive cancers. Notably, HPV-positive cancer cells can induce a dormant state under hypoxia, characterized by a reversible growth arrest and strong repression of viral E6/E7 oncogene expression, which could contribute to therapy resistance, immune evasion and tumor recurrence. The present work aimed to gain mechanistic insights into the pathway(s) underlying HPV oncogene repression under hypoxia. We show that E6/E7 downregulation is mediated by hypoxia-induced stimulation of AKT signaling. Ablating AKT function in hypoxic HPV-positive cancer cells by using chemical inhibitors efficiently counteracts E6/E7 repression. Isoform-specific activation or downregulation of AKT1 and AKT2 reveals that both AKT isoforms contribute to hypoxic E6/E7 repression and act in a functionally redundant manner. Hypoxic AKT activation and consecutive E6/E7 repression is dependent on the activities of the canonical upstream AKT regulators phosphoinositide 3-kinase (PI3K) and mechanistic target of rapamycin (mTOR) complex 2 (mTORC2). Hypoxic downregulation of E6/E7 occurs, at least in part, at the transcriptional level. Modulation of E6/E7 expression by the PI3K/mTORC2/AKT cascade is hypoxia specific and not observed in normoxic HPV-positive cancer cells. Quantitative proteome analyses identify additional factors as candidates to be involved in hypoxia-induced activation of the PI3K/mTORC2/AKT signaling cascade and in the AKT-dependent repression of the E6/E7 oncogenes under hypoxia. Collectively, these data uncover a functional key role of the PI3K/mTORC2/AKT signaling cascade for viral oncogene repression in hypoxic HPV-positive cancer cells and provide new insights into the poorly understood cross talk between oncogenic HPVs and their host cells under hypoxia. Oncogenic HPV types are major human carcinogens. Under hypoxia, HPV-positive cancer cells can repress the viral E6/E7 oncogenes and induce a reversible growth arrest. This response could contribute to therapy resistance, immune evasion, and tumor recurrence upon reoxygenation. Here, we uncover evidence that HPV oncogene repression is mediated by hypoxia-induced activation of canonical PI3K/mTORC2/AKT signaling. AKT-dependent downregulation of E6/E7 is only observed under hypoxia and occurs, at least in part, at the transcriptional level. Quantitative proteome analyses identify additional factors as candidates to be involved in AKT-dependent E6/E7 repression and/or hypoxic PI3K/mTORC2/AKT activation. These results connect PI3K/mTORC2/AKT signaling with HPV oncogene regulation, providing new mechanistic insights into the cross talk between oncogenic HPVs and their host cells.
缺氧与许多肿瘤实体的治疗抵抗和不良临床预后有关,包括人乳头瘤病毒(HPV)阳性癌症。值得注意的是,HPV 阳性癌细胞在缺氧下可以诱导休眠状态,其特征是可逆的生长停滞和对病毒 E6/E7 癌基因表达的强烈抑制,这可能导致治疗抵抗、免疫逃逸和肿瘤复发。本工作旨在深入了解 HPV 癌基因在缺氧下抑制的机制途径。我们表明,E6/E7 的下调是由缺氧诱导的 AKT 信号转导刺激介导的。使用化学抑制剂在缺氧的 HPV 阳性癌细胞中消除 AKT 功能,可有效抵抗 E6/E7 的抑制。AKT1 和 AKT2 的同工型特异性激活或下调表明,两种 AKT 同工型都有助于缺氧时 E6/E7 的抑制,并以功能上冗余的方式发挥作用。缺氧时 AKT 的激活和随后的 E6/E7 抑制依赖于经典上游 AKT 调节剂磷脂酰肌醇 3-激酶(PI3K)和雷帕霉素靶蛋白(mTOR)复合物 2(mTORC2)的活性。缺氧时 E6/E7 的下调至少部分发生在转录水平。PI3K/mTORC2/AKT 级联对 E6/E7 的调节是缺氧特异性的,在常氧 HPV 阳性癌细胞中观察不到。定量蛋白质组分析确定了其他因子作为候选因子,这些因子可能参与缺氧诱导的 PI3K/mTORC2/AKT 信号级联的激活以及 AKT 依赖性 E6/E7 癌基因在缺氧下的抑制。总之,这些数据揭示了 PI3K/mTORC2/AKT 信号级联在缺氧的 HPV 阳性癌细胞中对病毒癌基因抑制的功能关键作用,并为 HPV 致癌病毒与缺氧下宿主细胞之间尚未充分了解的相互作用提供了新的见解。致癌 HPV 类型是人类主要的致癌物质。在缺氧下,HPV 阳性癌细胞可以抑制病毒 E6/E7 癌基因并诱导可逆的生长停滞。这种反应可能导致治疗抵抗、免疫逃逸和再氧合时肿瘤复发。在这里,我们发现证据表明,HPV 癌基因的抑制是由缺氧诱导的经典 PI3K/mTORC2/AKT 信号转导激活介导的。只有在缺氧下才观察到 AKT 依赖性 E6/E7 下调,并且至少部分发生在转录水平。定量蛋白质组分析确定了其他因子作为候选因子,这些因子可能参与 AKT 依赖性 E6/E7 抑制和/或缺氧 PI3K/mTORC2/AKT 激活。这些结果将 PI3K/mTORC2/AKT 信号与 HPV 癌基因调控联系起来,为致癌 HPV 与宿主细胞之间的相互作用提供了新的机制见解。